MK-677 (Ibutamoren): Honest Assessment of Who It’s For and Who Should Skip It

Quick Review: MK-677 (Ibutamoren)

A legitimate GH secretagogue that works — and that comes with real tradeoffs most people glossed over when Huberman put it on the map. Conditional yes for men over 45 with documented low IGF-1 who’ve already run a full lifestyle optimization protocol. A clear no for men with insulin resistance, men in active fat loss phases, or anyone who hasn’t done the foundational work first.

• Best for: Men 45+ with IGF-1 confirmed low after 6+ months of optimized sleep, training, and body composition. Not a starter compound.
• Dosage I use with clients: 12.5mg taken 30-60 minutes before bed, not in the morning. Titrate up to 25mg only if 12.5mg is well-tolerated at 8 weeks.
• Cycling protocol: 12 weeks on, 6 weeks off minimum. Never run it indefinitely. Insulin markers tested at weeks 4 and 12 on-cycle.
• Would I recommend it: Conditionally, for a specific profile. I’d estimate 30-40% of the men who ask me about it actually qualify for that profile.

When Andrew Huberman discussed MK-677 on his podcast, the compound went from niche fitness-industry curiosity to mainstream search term almost overnight. The Huberman halo effect is real, and in this case it sent a lot of men toward a compound without the surrounding context that makes it useful versus counterproductive.

I’m not writing this to be contrarian. MK-677 does what it’s supposed to do. But the framing that gets most people excited about it — “oral GH secretagogue, raises IGF-1, take it before bed” — is incomplete in ways that matter significantly for the men who are most likely to try it.

What MK-677 Actually Is

MK-677, sold under the research chemical name Ibutamoren, is a (ghrelin mimetic — a compound that binds to the ghrelin receptor and triggers the same GH-releasing response that ghrelin, the hunger hormone, would produce) ghrelin mimetic. It’s not a GHRH analog like sermorelin. It works through a different receptor pathway, which is why its effects differ somewhat from peptides like CJC-1295 or Ipamorelin.

The mechanism works: binding the ghrelin receptor at the pituitary gland increases GH pulse amplitude. IGF-1 rises measurably within 4-6 weeks at clinical doses. Unlike injected GH secretagogues, it’s oral, which is why it attracted so much consumer interest when it entered the public conversation.

It’s not approved for human use by the FDA. It’s classified as a research chemical. That means no pharmaceutical-grade supply chain, no regulated dosing standards, and no long-term human safety data beyond the clinical trials that established its GH-raising mechanism. That context matters and I’ll come back to it.

What the Podcast Coverage Left Out

The insulin resistance problem is the primary one. MK-677 mimics ghrelin, and ghrelin is an appetite-stimulating, insulin-sensitizing-negatively compound in many contexts. Several clinical studies on MK-677 documented significant increases in fasting glucose and insulin over extended use periods. This isn’t a fringe finding — it’s consistent across the available trials.

For a man who comes to me with fasting insulin at 12-14 µIU/mL and HbA1c trending upward, adding a compound that increases insulin resistance is working directly against the metabolic correction I’m trying to achieve. The IGF-1 goes up. The insulin resistance goes up. Net hormonal effect is ambiguous at best, harmful at worst — because (hyperinsulinemia, or chronically elevated insulin, suppresses GH secretion by increasing somatostatin, the GH-blocking hormone) hyperinsulinemia suppresses the very GH pulses MK-677 is meant to stimulate.

In other words: if your metabolic health isn’t already solid, MK-677 can create a situation where you’re spending money on a compound to raise GH while simultaneously making your metabolism worse at producing GH naturally. That’s a poor trade.

The water retention is the second issue. Most users retain 3-6 lbs of water in the first 4-8 weeks. This isn’t fat — it’s glycogen and water shift — and it reverses on cessation. But it complicates body composition assessment and can cause enough visual bloat that men misread what’s happening. For men in active fat loss phases, the water weight shift is demoralizing and confusing.

The appetite increase is real. Ghrelin drives hunger. Mimicking ghrelin at 25mg per day substantially increases appetite in most users. For men trying to maintain a caloric deficit, this is a meaningful obstacle.

The Clients I’ve Used It With

Hank Vargas came to me at 48 wanting TRT. He’d already booked a consultation at a clinic. I asked him for six months of the natural protocol before making that call, and he reluctantly agreed. By month four, T was at 660 and IGF-1 at 138 — his T problem was primarily lifestyle-driven and resolved cleanly. But at his eight-month retest, IGF-1 was still at 142. For a man his age and physical history — 12 years active duty in the Marines, private security work, a body that’s taken a lot of wear — I expected more movement.

Hank was the right candidate for a MK-677 trial. Insulin sensitivity was excellent (fasting insulin 6.2, HbA1c 5.1), he slept well, he wasn’t trying to cut body fat, and he had confirmed low-normal IGF-1 after six months of optimized lifestyle. We ran 12.5mg before bed for 12 weeks, retesting at weeks 4 and 12. IGF-1 moved from 142 to 186 ng/mL. He retained about 4 lbs of water in the first 6 weeks, then stabilized. No meaningful insulin marker change at either test. Cycled off at 12 weeks, rechecked at week six of the off-period: IGF-1 had settled at 158 — higher than pre-cycle, lower than peak.

That last part is important. MK-677 is not a permanent fix. It raises IGF-1 while you’re on it. When you cycle off, the numbers don’t stay at peak values. The benefit is real but it exists only while you’re running the compound.

Doug Sterling was the case where I said no. Doug at 52 — recently divorced, had lost 30 lbs in the year before coming to me, was drinking too much and depressively detached from any consistent lifestyle. His fasting insulin was 14.8, HbA1c 5.8 — not diabetic but trending in a direction I didn’t like. He read about MK-677 and asked if it would help with his body composition and energy. My answer was no, for now, and here’s why: his insulin resistance was already working against his GH production. Adding a compound that would worsen that resistance while claiming to raise GH was backwards. We spent seven months correcting his metabolic markers first. Fasting insulin eventually came down to 8.4. Only then did the conversation about whether to trial MK-677 become worth having — and by that point, his IGF-1 had already improved from lifestyle changes alone.

Sam Reichert is the case I use most when explaining who doesn’t need MK-677. Sam is 29, a PhD student in chemistry, vegetarian, analytical to a fault. He asked about MK-677 with a detailed written question comparing its mechanism to sermorelin. I told him to run his bloodwork first. IGF-1 was at 132 ng/mL — below where I’d want it for a 29-year-old, but his ferritin was 28 (low), vitamin D was 18 ng/mL (very low), and he’d never structured his training in any meaningful way. We corrected the deficiencies and built a basic 6-12-25 training structure. Six months later, IGF-1 was at 198. He never needed MK-677. He needed the foundational work he’d skipped because it was less interesting to him than research chemical mechanisms.

The Leptin Sensitivity Question

There’s an underappreciated risk with longer-term MK-677 use that doesn’t get discussed much outside research circles. (Leptin is the satiety hormone released by fat tissue that signals fullness to the brain — leptin sensitivity determines how well your body reads those signals) Leptin sensitivity can degrade with chronic ghrelin receptor agonism. Since ghrelin and leptin are counter-regulatory hormones — ghrelin drives hunger, leptin drives satiety — running a ghrelin mimetic for extended periods may blunt the satiety signaling that keeps appetite regulation intact.

This is one reason I cap cycles at 12 weeks with a minimum 6-week off-period. I don’t have long-term client data beyond 18 months of on-off cycling, but the clinical trial data that exists suggests that extended continuous use produces progressively less favorable metabolic profiles. The GH stimulus appears to diminish somewhat with continuous use anyway — another reason cycling makes more pharmacological sense than indefinite dosing.

Sleep Timing and Why It Matters

Taking MK-677 in the morning — which some protocols recommend — is, in my opinion, a mistake for most users. GH is released in pulses, with the largest pulse occurring during slow-wave sleep in the first third of the night. MK-677 augments GH pulse amplitude. Taking it at night, 30-60 minutes before sleep, positions the peak ghrelin receptor agonism to coincide with the natural nocturnal GH pulse, amplifying the effect rather than creating a daytime pulse that competes with the body’s rhythm rather than supporting it.

The appetite stimulation from nighttime dosing is also attenuated — most users report that hunger effects are substantially lower when they dose at night versus morning, because the ghrelin receptor activation occurs during sleep rather than during the waking hours when food is accessible.

Who Actually Qualifies

Based on what I’ve seen work and what I’ve seen fail, here’s the profile of men for whom I’d consider a MK-677 trial:

• Age 45 or older, with IGF-1 confirmed low-normal after 6+ months of optimized sleep, structured training, and corrected deficiencies
• Fasting insulin below 10 µIU/mL and HbA1c below 5.5% at baseline
• Not currently in an active fat loss phase (the appetite stimulation and water retention conflict with that goal)
• Sleeping consistently — 7+ hours, reasonable sleep quality. MK-677’s GH amplification depends on the nocturnal pulse being intact
• Willing to test insulin markers at weeks 4 and 12 on-cycle, and to stop if insulin resistance markers worsen

If a man doesn’t meet all five of those criteria, my recommendation is to address whichever criteria he doesn’t meet before considering the compound. In most cases, addressing those criteria also moves IGF-1 enough that the compound becomes unnecessary.

That’s the honest assessment. PowerandBulk.com covers GH optimization in more depth across several articles in this cluster, and Anabolic Alchemy sequences the full protocol with decision trees for when to consider secretagogues versus lifestyle optimization alone. The starting point is always the same: run the lifestyle protocol that addresses the actual drivers of low IGF-1 first. MK-677 is a tool for men who’ve done that work and still have room to move. It’s not a shortcut for men who haven’t.

Hank understood that. Doug got there eventually. Sam never needed it at all. Most men asking about MK-677 are closer to Sam’s situation than they think — they just haven’t run the foundational protocol long enough to find out.